| CML V TIGER-Study | A prospective, randomized, open-label, multicenter therapeutic study comparing nilotinib with and without interferon as induction therapy, and nilotinib versus interferon as maintenance therapy for the treatment of chronic myeloid leukemia (CML). |
| DasaHIT-Study | A prospective, randomized, open-label, multicenter dasatinib dose-optimization study to evaluate the tolerability and efficacy of medication taken on 5 out of 7 days of the week versus daily dosing in patients with CML. |
| FASCINATION-Study | Prospective, non-randomized, open-label, multicenter study of deep molecular response in CML patients treated with a combination of an established tyrosine kinase inhibitor and asciminib. |
| TRACE-Study | A prospective, randomized, double-blind, placebo-controlled, multicenter study of the efficacy of multi-specific T-cell infusion against chemo-refractory viral infections following allogeneic stem cell transplantation. |
| NAUT-Study | Prospective, open-label, multicenter registry study to investigate the feasibility of discontinuing therapy again in CML patients who relapsed after the first discontinuation of therapy but subsequently achieved deep remission following renewed nilotinib therapy lasting at least two years. |
| PONTrack-Study | Prospective, open-label, multicenter registry study on deep molecular response in CML patients who have received 2 years of ponatinib treatment. |
| CML-TFR-Registry | A registry for the prospective assessment of treatment-free molecular remission status in CML, with the aim of investigating prognostic factors. |
| International CML Genomics Alliance | Global genomic data to evaluate the clinical relevance of pathogenic variants at the time of diagnosis of CML in the chronic phase with regard to events such as the occurrence of BCR::ABL1 kinase domain mutations, disease progression, or death. |
| ESTIMATION-Study | Registry for the prospective assessment of molecular remission success in CML patients with the T315I mutation who are being treated with asciminib. |
| EURO-SKI-Study | Registry for prognostic research on the maintenance of molecular remission in CML patients following discontinuation of therapy. |
| ELN/EUTOS-Registry | A registry for prognostic research on prospectively enrolled CML patients treated predominantly with imatinib and their outcomes over the course of therapy. |